News

NTLA Lawsuit Alert! Class Action Lawsuit Against Intellia Therapeutics Inc.
A class action lawsuit was filed against Intellia Therapeutics Inc. (NTLA) by Levi & Korsinsky on February 11, 2025. The ...
Yahoo Finance15d
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies ...
Clinical Trials Arena on MSN14d
Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN
Intellia Therapeutics has commenced subject dosing in the Phase III MAGNITUDE-2 trial of nexiguran ziclumeran (nex-z) for ...
Yahoo Finance19d
Intellia Focuses on Pipeline Development Amid Stiff Competition
Intellia Therapeutics, Inc. NTLA is developing its lead CRISPR-based, in vivo genome-editing candidate, nexiguran ziclumeran (nex-z, formerly known as NTLA-2001) for the treatment of transthyretin ...
Pharmabiz13d
Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran
Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran: Cambridge, Massachusetts Saturday, April 5, 2025, 18:00 Hrs [IST] Intellia Therapeu ...
Seeking Alpha23d
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR ...
March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today ...
Finanznachrichten15d
Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies ...
pharmaphorum1d
CRISPR biotech Intellia cuts staff as it eyes 2027 launch
Intellia Therapeutics has said it will reduce its ... its resources behind two priority drug candidates. The specialist in CRISPR-based gene editing – co-founded by Nobel Prize winner Jennifer ...